

# Sherene Loi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/544541/sherene-loi-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232  
papers

30,946  
citations

77  
h-index

175  
g-index

263  
ext. papers

39,912  
ext. citations

10.1  
avg, IF

6.93  
L-index

#	Paper	IF	Citations
232	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2108-2121	59.2	1871
231	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 262-72	9.7	1485
230	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , <b>2015</b> , 26, 259-71	10.3	1372
229	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 860-7	2.2	1023
228	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1183-92	9.7	976
227	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 209-19	59.2	940
226	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1009-1021	21.7	931
225	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1544-50	10.3	780
224	Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3207-14	12.9	759
223	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 983-91	2.2	650
222	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1239-46	2.2	650
221	CD4+ follicular helper T cell infiltration predicts breast cancer survival. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2873-92	15.9	554
220	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotarget</i> , <b>2014</b> , 5, e955691	7.2	524
219	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1009-1021	21.7	492
218	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1926-1936	59.2	478
217	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 228-41	19.4	429
216	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 44-59	21.7	422

215	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2961-8	2.2	420
214	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , <b>2018</b> , 24, 986-993	50.5	420
213	Clinical application of the 70-gene profile: the MINDACT trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 729-35	396	
212	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 597-609	59.2	396
211	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , <b>2018</b> , 554, 189-194	50.4	388
210	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. <i>JAMA Oncology</i> , <b>2015</b> , 1, 448-54	13.4	359
209	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , <b>2019</b> , 567, 479-485	50.4	358
208	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 7142-7	11.5	334
207	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , <b>2012</b> , 18, 1224-31	50.5	322
206	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , <b>2019</b> , 30, 397-404	10.3	313
205	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1499-509	12.9	311
204	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1817-1828	40	306
203	Dissecting the heterogeneity of triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1879-87	2.2	304
202	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 11091-6	11.5	303
201	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Myeloid Tumor. <i>Early View of the International Journal of Cancer</i> , <b>2017</b> , 141, 235	5.1	299
200	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ. <i>Metastatic Tumor: Diagnosis and Treatment of Early-Stage Breast Cancer</i> , <b>2017</b> , 141, 235	5.1	293
199	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 10208-13	11.5	293
198	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 559-569	2.2	282

197	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , <b>2008</b> , 9, 239	4.5	272
196	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 935-46	14.4	259
195	Obesity and outcomes in premenopausal and postmenopausal breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1686-91	4	253
194	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , <b>2019</b> , 30, 405-411	10.3	246
193	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. <i>Cancer Research</i> , <b>2011</b> , 71, 4809-20	10.1	239
192	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1341-51	12.9	239
191	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death <b>2020</b> , 8,		233
190	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1390-1403	24.4	231
189	A three-gene model to robustly identify breast cancer molecular subtypes. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 311-25	9.7	218
188	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , <b>2006</b> , 3, 540-51		202
187	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 693-704	19.4	201
186	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 371-382	21.7	200
185	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 506-17	12.5	198
184	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3212-20	2.2	189
183	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 929-941	15.9	183
182	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , <b>2018</b> , 52, 16-25	12.7	181
181	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	167
180	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2804-2811	12.9	167

179	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1996-2004	2.2	167
178	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 52-62	21.7	164
177	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1334-9	2.2	164
176	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 519-530	21.7	159
175	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , <b>2016</b> , 29, 1155-64	9.8	154
174	Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 28-33	12.9	147
173	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , <b>2016</b> , 21, 1165-1175	5.7	140
172	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 487-504	12.9	138
171	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , <b>2015</b> , 13, 202	11.4	131
170	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , <b>2016</b> , 29, 241-503	3.6	130
169	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1169-1178	2.2	127
168	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 960-7	9.7	112
167	RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 24	8.3	109
166	Combined CDK4/6 and PI3K inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 6340-6352	10.1	99
165	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , <b>2016</b> , 76, 4372-82	10.1	94
164	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1000-1000	2.2	92
163	Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 845-9	5.8	85
162	Intratumoral heterogeneity in cancer progression and response to immunotherapy. <i>Nature Medicine</i> , <b>2021</b> , 27, 212-224	50.5	84

161	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , <b>2020</b> , 250, 667-684	9.4	83
160	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. <i>Oncologist</i> , <b>2017</b> , 22, 1028-1038	5.7	83
159	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1008-1008	2.2	82
158	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002204	11.6	81
157	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2017</b> , 3, 227-234	13.4	79
156	Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. <i>OncImmunology</i> , <b>2013</b> , 2, e24720	7.2	79
155	Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. <i>PLoS ONE</i> , <b>2008</b> , 3, e2987	3.7	77
154	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 201	8.3	75
153	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 1054-1062	50.5	74
152	Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. <i>Molecular Endocrinology</i> , <b>2013</b> , 27, 350-65		73
151	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 121	8.3	73
150	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 341-348	19.4	70
149	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	69
148	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , <b>2017</b> , 49, 141-155	1.6	68
147	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	68
146	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , <b>2020</b> , 587, 126-132	50.4	67
145	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 43	8.3	67
144	Identification of novel Ras-cooperating oncogenes in <i>Drosophila melanogaster</i> : a RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis. <i>Genetics</i> , <b>2011</b> , 188, 105-25	4	65

143	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 70	8.4	64
142	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , <b>2017</b> , 77, 5652-5663	10.1	64
141	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). <i>Breast</i> , <b>2017</b> , 34 Suppl 1, S27-S30	3.6	64
140	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 156	5.3	64
139	Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context. <i>BMC Bioinformatics</i> , <b>2010</b> , 11, 277	3.6	64
138	PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e53292	3.7	64
137	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1283-1295	21.7	62
136	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , <b>2015</b> , 236, 457-466	6.6	61
135	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 981-990	2.2	61
134	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 606	17.4	60
133	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1005-1016	9.7	56
132	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 768-776	9.7	55
131	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 4-11	8.7	55
130	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 17	7.8	54
129	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). <i>European Journal of Cancer</i> , <b>2017</b> , 85, 133-145	7.5	54
128	Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 305-315	3.9	53
127	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e240-8	21.7	51
126	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, 545-54	5.7	48

125	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1040-7	13.4	48
124	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 16	7.8	47
123	Phase 2 study of pembrolizumab as first-line therapy for PD-L1 $\beta$ positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1088-1088	2.2	47
122	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. <i>Cancer Research</i> , <b>2017</b> , 77, 1296-1309	10.1	46
121	Beyond trastuzumab: new treatment options for HER2-positive breast cancer. <i>Breast</i> , <b>2011</b> , 20 Suppl 3, S20-7	3.6	46
120	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 1010-1014	44.5	46
119	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 198-213	24.4	41
118	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2 breast cancer metastasis. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 94	8.3	41
117	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 871-884	12.5	41
116	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1860-6	10.3	40
115	Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. <i>BMC Medical Genomics</i> , <b>2009</b> , 2, 37	3.7	39
114	Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1004-14	12.9	39
113	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 1069-1081	12.5	38
112	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 623-34	4.2	38
111	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , <b>2017</b> , 30, 952-963	9.8	37
110	The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. <i>Critical Reviews in Oncology/Hematology</i> , <b>2007</b> , 61, 187-94	7	37
109	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , <b>2020</b> , 1, 546-561	15.4	37
108	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , <b>2018</b> , 104, 21-31	7.5	37



107	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTT0 Phase III Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3581-3588	12.9	36
106	Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. <i>Oncotarget</i> , <b>2016</b> , 7, 67686-67698	3.3	36
105	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , <b>2015</b> , 13, 177	11.4	35
104	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 419-430	9.7	32
103	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , <b>2018</b> , 11,	8.8	32
102	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , <b>2019</b> , 65, 1405-1413	5.5	31
101	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2017</b> , 1868, 527-537	11.2	29
100	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1954-60	2.2	28
99	Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). <i>Breast</i> , <b>2019</b> , 48 Suppl 1, S44-S48	3.6	26
98	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 152, 95-117	4.4	25
97	Mouse Models of Tumor Immunotherapy. <i>Advances in Immunology</i> , <b>2016</b> , 130, 1-24	5.6	25
96	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , <b>2020</b> , 49, 55-62	3.6	25
95	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , <b>2016</b> , 76, 4236-48	10.1	25
94	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1335-1343	13.4	24
93	CD73: A potential biomarker for anti-PD-1 therapy. <i>OncolImmunology</i> , <b>2015</b> , 4, e1046675	7.2	23
92	Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <i>OncoTargets and Therapy</i> , <b>2010</b> , 4, 1-11	4.4	22
91	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	21
90	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 174, 271-278	4.4	21

89	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) <b>2020</b> ,		19
88	Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 354-363	12.9	19
87	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 309-317	9.7	19
86	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , <b>2015</b> , 24, 290-3	3.6	18
85	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. <i>Cancer Research</i> , <b>2016</b> , 76, 264-74	10.1	17
84	Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 2813-8	7.5	17
83	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 150	7.8	17
82	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5668-5681	12.9	17
81	Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 3-5	21.7	17
80	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , <b>2020</b> , 80, 1304-1315	10.1	16
79	Molecular forecasting of breast cancer: time to move forward with clinical testing. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 721-2; author reply 722-3	2.2	16
78	Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. <i>Medicine and Science in Sports and Exercise</i> , <b>2019</b> , 51, 1573-1581	1.2	16
77	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , <b>2020</b> , 11, 6335	17.4	15
76	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1162-8	21.7	15
75	HER2-overexpressing breast cancer: time for the cure with less chemotherapy?. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 547-58	4.2	15
74	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 936-44	2.2	14
73	Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 562-7	4.2	13
72	Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , <b>2004</b> , 16, 536-41	4.2	13

71	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , <b>2017</b> , 18, 35	5.4	12
70	Glomerulosclerosis: a paraneoplastic phenomenon?. <i>Nephrology</i> , <b>2004</b> , 9, 387-91	2.2	12
69	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , <b>2020</b> , 22, 91	8.3	12
68	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , <b>2012</b> , 7, 267-72	2.4	11
67	Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 <b>2020</b> ,		11
66	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , <b>2015</b> , 6, 30306-16	3.3	11
65	Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Cell</i> , <b>2020</b> , 37, 623-624	24.3	10
64	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , <b>2014</b> , 23, 473-81	3.6	10
63	Breast cancer gene expression profiling: clinical trial and practice implications. <i>Pharmacogenomics</i> , <b>2005</b> , 6, 49-58	2.6	10
62	PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA502-LBA502	2.2	10
61	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811	24.4	10
60	The adverse mental health of carers: Does the patient diagnosis play a role?. <i>Maturitas</i> , <b>2015</b> , 82, 134-8	5	9
59	Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data. <i>Genome Biology</i> , <b>2014</b> , 15, 470	18.3	9
58	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. <i>Oncologist</i> , <b>2021</b> , 26, e749-e755	5.7	9
57	Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 298-301	3.8	9
56	Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer <b>2021</b> ,		9
55	Molecular comparison of interval and screen-detected breast cancers. <i>Journal of Pathology</i> , <b>2019</b> , 248, 243-252	9.4	8
54	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 15	7.8	8

53	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e181564	13.4	8
52	Gene profiling assay and application: the predictive role in primary therapy. <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 124-7	4.8	8
51	The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1006-1006	2.2	8
50	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , <b>2017</b> , 1,	3.6	7
49	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003363	11.6	7
48	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Update for 2020. <i>Cancer Journal (Sudbury, Mass )</i> , <b>2021</b> , 27, 25-31	2.2	7
47	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 721-30	5.7	6
46	Novel Targeted Agents and Immunotherapy in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 65-75	7.1	6
45	Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 266-276	7.5	6
44	INPP4B promotes PI3K-dependent late endosome formation and Wnt/ $\beta$ -catenin signaling in breast cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 3140	17.4	6
43	Novel Targeted Agents and Immunotherapy in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 65-75	7.1	5
42	The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 23	7.8	5
41	A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 407-14	3.5	5
40	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 516-516	2.2	5
39	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	5
38	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12 Suppl 1, 3-18	1.9	5
37	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 599-606	4.4	5
36	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 3	7.8	4

35	Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 511-511	2.2	4
34	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 945-962	5.4	4
33	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , <b>2021</b> , 59, 183-192	3.6	4
32	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 72, 95-102	7.5	3
31	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.. <i>European Urology</i> , <b>2021</b> ,	10.2	3
30	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 510-510	2.2	3
29	Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1055-1055	2.2	3
28	Metastatic Breast Cancer: TIL it is Too Late. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 526-528	12.9	3
27	Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BREast cancer EXercise INtervention (BREXIT) trial protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 655	4.8	3
26	Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2019</b> , 15, 377-382	1.9	2
25	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203346	3.7	2
24	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101536	2.2	2
23	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. <i>Current Breast Cancer Reports</i> , <b>2015</b> , 7, 59-70	0.8	1
22	Time to move forward from "first-generation" prognostic gene signatures in early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 643-5	4.4	1
21	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.. <i>European Journal of Cancer</i> , <b>2022</b> , 164, 39-51	7.5	1
20	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS1134-TPS1134	2.2	1
19	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 613-613	2.2	1
18	Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	1

17	Fine-tuning chemotherapy in the era of dual HER2 targeting. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1551-1554	21.7	1
16	Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 15	8.3	1
15	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5607-5618	12.9	0
14	PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer.. <i>Science Advances</i> , <b>2022</b> , 8, eabk3338	14.3	0
13	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 219-228	7.5	0
12	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2022</b> , 1-13	7.1	0
11	Immunology and Immunotherapy of Breast Cancer <b>2015</b> , 457-470		
10	Reply to A. Ocañ et al and P.G. Tsoutsou et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1299-300	2.2	
9	Molecular segmentation of luminal breast: Reality in 2015?. <i>Breast</i> , <b>2015</b> , 24 Suppl 2, S41-3	3.6	
8	Conference Scene: Advances in breast cancer translational research. <i>Breast Cancer Management</i> , <b>2012</b> , 1, 197-199	0.7	
7	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 630-630	2.2	
6	Evaluation of PI3K-pathway activation status in matched primary (P) and metastatic (M) ER+/HER2-breast cancer (BC) lesions according to PIK3CA-mutation status.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11060-11060	2.2	
5	Gene Expression Analysis: Applications <b>2016</b> , 137-149		
4	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11061-11061	2.2	
3	Extended adjuvant aromatase inhibitor therapy: less is more.. <i>Med</i> , <b>2021</b> , 2, 996-998	31.7	
2	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. <i>Cancer Research</i> , <b>2022</b> , 82, P5-19-03-P5-19-03	10.1	
1	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200284	2.2	